Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioNTech SE

105.35
-3.4300-3.15%
Post-market: 104.80-0.5500-0.52%19:42 EDT
Volume:1.17M
Turnover:123.68M
Market Cap:25.26B
PE:-48.66
High:107.46
Open:105.77
Low:103.48
Close:108.78
Loading ...

Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations

GlobeNewswire
·
28 Feb

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire
·
28 Feb

Warburg Research Sticks to Its Buy Rating for Commerzbank (0RLW)

TIPRANKS
·
28 Feb

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

PR Newswire
·
28 Feb

Bear of the Day: Krispy Kreme (DNUT)

Zacks
·
28 Feb

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

NewMediaWire
·
28 Feb

Invivyd (NasdaqGM:IVVD) Surges 198% After Positive Results From VYD2311 COVID-19 Trial

Simply Wall St.
·
28 Feb

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Benzinga
·
28 Feb

CVS Pharmacy® introduces enhanced flu testing and treatment offerings

PR Newswire
·
27 Feb

Deutsche Pfandbriefbank (0R9K) Receives a Buy from Warburg Research

TIPRANKS
·
27 Feb

Medibank Announces $160 Million Customer Give Back Amid COVID-19 Support

TIPRANKS
·
27 Feb

BioNTech SE (BNTX): Among the Best Vaccine Stocks to Buy According to Hedge Funds

Insider Monkey
·
26 Feb

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

GlobeNewswire
·
26 Feb

OraSure Reports Fourth Quarter 2024 Financial Results

GlobeNewswire
·
26 Feb

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire
·
24 Feb

Invivyd’s Strategic Positioning and Growth Potential in COVID-19 Prophylaxis Market: A Buy Rating Despite Regulatory Challenges

TIPRANKS
·
24 Feb